Colorectal Cancer-GVAX - Healing Genes

Colorectal Cancer-GVAX

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

GVAX for Colorectal Cancer

A Pilot Safety Study of Vaccination With Autologous, Lethally Irradiated Colorectal Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating Factor

Phase 1


Doctors at Massachusetts General Hospital seek patients with colorectal cancer with liver metastases to trial therapeutic, autologous (to the self), gene-modified vaccines. The vaccines are cells taken from the patient’s tumor, gene-modified to produce an anti-tumor protein that stimulates the immune system to attack the cancer, then injected back to the patient.

Study participants will receive up to 6 injections of the vaccine after it is made from their tumor cells, then be followed for 2 to 10 years.


  • Be 18 years of age or older
  • Not have active autoimmune disease
  • Be at least 4 weeks since last dose of chemotherapy, radiotherapy, immunotherapy, systemic glucocorticoid therapy or operation in order to receive vaccine
  • Not have hepatic metastases involving both branches of the portal vein or all three hepatic veins


  1. Screening to confirm acceptance to the study.
  2. Recovery of tumor cells and genetic modification in the lab to prepare vaccine therapy.
  3. Intravenous injections will be scheduled, 6 in total.
  4. Follow up will continue for 2 to 10 years including physical, lab, and overall survival assessments.

The study location is at Massachusetts General Hospital in Boston, MA, Map.
Contact: Cristina Ferrone, MD  |  6176436189  |  [email protected]
Massachusetts General Hospital
Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader